AXON Neuroscience

Executive Summary

AXON Neuroscience SE is a clinical-stage biotechnology company based in Bratislava, Slovakia, founded in 1999. The company specializes in developing disease-modifying immunotherapies and early diagnostics for Alzheimer's disease, with a unique focus on targeting pathological tau protein. Unlike many competitors that target amyloid beta, AXON's tau-directed approach aims to halt disease progression, relieve symptoms, and potentially prevent onset. The company's lead candidate is currently in Phase 3 clinical trials, positioning it as a potential first-in-class therapy if successful. AXON has operated as a private entity for over two decades, accumulating significant expertise in tau biology and immunotherapy.

Upcoming Catalysts (preview)

• TBDPhase 3 Topline Data Readout35% success
• TBDPartnership or Licensing Agreement50% success
• TBDRegulatory Designation (FDA Fast Track or EMA PRIME)70% success